Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All famotidine studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchFamotidineFamotidine (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 11% Improvement Relative Risk Ventilation 12% ICU admission 10% Hospitalization time 17% Recovery time 10% Famotidine  Pahwani et al.  LATE TREATMENT  RCT Is late treatment with famotidine beneficial for COVID-19? RCT 178 patients in Pakistan (December 2020 - September 2021) Shorter hospitalization (p<0.0001) and faster recovery (p=0.0011) c19early.org Pahwani et al., Cureus, February 2022 Favors famotidine Favors control

Efficacy of Oral Famotidine in Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2

Pahwani et al., Cureus, doi:10.7759/cureus.22404
Feb 2022  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Famotidine for COVID-19
26th treatment shown to reduce risk in October 2021
 
*, now known with p = 0.00026 from 30 studies.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments. c19early.org
RCT with 89 famotidine and 89 control patients in Pakistan, showing faster recovery but no significant difference in mortality. 40mg oral famotidine daily.
risk of death, 11.1% lower, RR 0.89, p = 1.00, treatment 8 of 89 (9.0%), control 9 of 89 (10.1%), NNT 89.
risk of mechanical ventilation, 12.5% lower, RR 0.88, p = 0.73, treatment 21 of 89 (23.6%), control 24 of 89 (27.0%), NNT 30.
risk of ICU admission, 10.0% lower, RR 0.90, p = 0.86, treatment 18 of 89 (20.2%), control 20 of 89 (22.5%), NNT 44.
hospitalization time, 16.5% lower, relative time 0.83, p < 0.001, treatment mean 8.6 (±1.6) n=89, control mean 10.3 (±2.2) n=89.
recovery time, 9.6% lower, relative time 0.90, p = 0.001, treatment mean 8.5 (±1.7) n=89, control mean 9.4 (±1.9) n=89.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Pahwani et al., 20 Feb 2022, Randomized Controlled Trial, Pakistan, peer-reviewed, mean age 52.0, 8 authors, study period December 2020 - September 2021.
This PaperFamotidineAll
Efficacy of Oral Famotidine in Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2
Suraksha Pahwani, Mahesh Jadwani, Aperna Dhanwani, Mehak Gul, Darshan Lal, Fnu Rakesh, Raffey Shabbir, Amber Rizwan
Cureus, doi:10.7759/cureus.22404
Introduction The clinical benefit of famotidine has been observed in the management of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, its use in the management of SARS-CoV-2 is intriguing and not well established yet. In this study, we aimed to determine the role of famotidine as adjuvant therapy in improving the outcome of patients hospitalized with coronavirus disease-2019 . Methods This two-arm open-label randomized interventional study was conducted in the COVID-19 unit of a tertiary care hospital in Pakistan from December 2020 to September 2021. Patients between the ages of 18 to 65 years, hospitalized with COVID-19 infection, were enrolled in the study. Participants were randomized into two groups. The intervention group received 40 mg oral famotidine daily in addition to the standard care and the control group received standard care as per national guidelines for the treatment of COVID-19 in Pakistan. Results Patients admitted with COVID-19 who received famotidine took comparatively fewer days to become symptom-free (8.5 ± 1.7 vs. 9.4 ± 1.9 days, p-value: <0.001) and spent fewer days in hospital (8.6 ± 1.6 vs. 10.3 ± 2.2 days; p-value: <0.0001). However, the overall difference in the need for mechanical ventilation and mortality between the interventional arm and placebo was not significant. Conclusion In this study, adding famotidine to standard treatment of COVID-19 was associated with faster clinical recovery and shorter stay in the hospital. However, there was no difference in the need for mechanical ventilation, need for intensive care unit, and overall mortality. Further large-scale studies are needed to understand the role of famotidine in COVID-19 and its mechanism of action in patients with COVID-19.
Conclusions In this study, adding famotidine to standard treatment of COVID-19 was associated with faster clinical recovery and shorter hospital stay. However, there was no difference in the need for mechanical ventilation, the need for ICU, and overall mortality. Further large-scale studies are needed to understand the role of famotidine in COVID-19 and its possible mechanism of action in patients with COVID-19. Additional Information Disclosures Human subjects: Consent was obtained or waived by all participants in this study. Jinnah Sindh Medical University Ethics Committee issued approval JSMU/IRB/2020/12. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
References
Ai, Yang, Hou, Correlation of chest CT and RT-PCR testing for coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases, Radiology, doi:10.1148/radiol.2020200642
Alonso, Zappia, Cabrera, Davio, Shayo et al., Physiological implications of biased signaling at histamine H2 receptors, Front Pharmacol, doi:10.3389/fphar.2015.00045
Balouch, Vontela, Yeakel, Alnouri, Sataloff, Role of famotidine and other acid reflux medications for SARS-CoV-2: a pilot study, doi:10.1016/j.jvoice.2021.01.007
Chakraborty, Sharma, Sharma, Bhattacharya, Lee, SARS-CoV-2 causing pneumoniaassociated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options, Eur Rev Med Pharmacol Sci, doi:10.26355/eurrev_202004_20871
Chan, Yip, To, Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp/Hel real-time reverse transcription-PCR assay validated in vitro and with clinical specimens, J Clin Microbiol, doi:10.1128/JCM.00310-20
Chen, Qi, Liu, Clinical progression of patients with COVID-19 in Shanghai, China, J Infect, doi:10.1016/j.jinf.2020.03.004
Freedberg, Conigliaro, Wang, Tracey, Callahan et al., Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: a propensity score matched retrospective cohort study, Gastroenterology, doi:10.1053/j.gastro.2020.05.053
Huang, Wang, Li, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, doi:10.1016/S0140-6736(20)30183-5
Krystel-Whittemore, Dileepan, Wood, Mast cell: a multi-functional master cell, Front Immunol, doi:10.3389/fimmu.2015.00620
Lei, Zhang, Yu, Patlas, COVID-19 infection: early lessons, Can Assoc Radiol J, doi:10.1177/0846537120914428
Lorenzo, Fernández-Hernando, Cirino, Sessa, Akt1 is critical for acute inflammation and histamine-mediated vascular leakage, Proc Natl Acad Sci U S A, doi:10.1073/pnas.0904073106
Luo, Chen, Zhao, Histamine H2 receptor activation exacerbates myocardial ischemia/reperfusion injury by disturbing mitochondrial and endothelial function, Basic Res Cardiol, doi:10.1007/s00395-013-0342-4
Malone, Tisdall, Smith, COVID-19: famotidine, histamine, mast cells, and mechanisms, doi:10.21203/rs.3.rs-30934/v2
Mather, Seip, Mckay, Impact of famotidine use on clinical outcomes of hospitalized patients with COVID-19, Am J Gastroenterol, doi:10.14309/ajg.0000000000000832
Pahwani, None, Cureus, doi:10.7759/cureus.224043of4
Pahwani, None, Cureus, doi:10.7759/cureus.224044of4
Salehi, Abedi, Balakrishnan, Gholamrezanezhad, Coronavirus disease 2019 (COVID-19): a systematic review of imaging findings in 919 patients, Am J Roentgenol, doi:10.2214/AJR.20.23034
Sun, Chen, Hu, Does famotidine reduce the risk of progression to severe disease, death, and intubation for COVID-19 patients? A systemic review and meta-analysis, Dig Dis Sci, doi:10.1007/s10620-021-06872-z
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit